Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical firm dedicated to improving mitochondrial health and protecting neuronal function, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The virtual presentation is scheduled for September 9, 2024, at 7 a.m. EST. Clene's management will also conduct 1x1 investor meetings during the event.
Clene, along with its wholly owned subsidiary Clene Nanomedicine Inc., focuses on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's investigational therapy CNM-Au8(R) aims to enhance the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway, while reducing oxidative stress.
The upcoming presentation offers Clene an opportunity to showcase its advancements in biopharmaceutical research to a global audience of investors. This is particularly significant as the company works on critical therapies for debilitating diseases like ALS and MS, which have limited treatment options.
Investors and stakeholders can view the webcast of the presentation by visiting https://ibn.fm/6ncBJ. For further information on Clene's developments and updates, visit their newsroom at https://ibn.fm/CLNN.
